Interstitial lung disease+2
Not yet recruitingCarboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease
Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease
- Disease:Interstitial lung diseaseNon-small cell lung cancer stage IV+1
- Substances:BevacizumabCarboplatin+6
France- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Intergroupe Francophone De Cancerologie Thoracique




